Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Tarsus Pharmaceuticals, Inc.
|
|
| Balance Sheet |
|
|
|
| Standardized | As Reported |
Annual | Quarterly |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Assets |
| Cash and equivalents | 106.8 | 66.0 | | 169.5 | 245.4 | 175.0 | 171.3 | 183.8 |
| Short-term investments | 71.5 | 135.2 | | 57.1 | | 0.3 | 0.5 | |
| Accounts receivable, net | | 2.5 | | 0.0 | 0.0 | 0.0 | | |
| Other current assets | 5.2 | 4.9 | | 7.5 | 4.9 | 3.4 | 4.1 | 3.3 |
| Total current assets | 183.5 | 208.6 | | 234.1 | 250.3 | 178.8 | 176.0 | 187.1 |
| Property, plant, and equipment, net | 1.5 | 1.2 | | 1.0 | 1.0 | 0.9 | 0.8 | 0.5 |
| Long-term investments | 0.3 | 0.3 | | 0.2 | 0.2 | | | |
| Other fixed assets | 1.5 | 0.5 | | 0.6 | 0.6 | 0.9 | 1.1 | 1.6 |
| Total assets | 188.9 | 211.2 | | 236.5 | 252.8 | 181.5 | 178.9 | 190.4 |
| |
| Accounts payable | 8.2 | 7.6 | | 5.6 | 4.1 | 4.0 | | 2.0 |
| Accrued expenses | 5.3 | 4.2 | | 4.1 | 2.8 | 1.8 | 2.8 | 2.2 |
| Short-term debt | 0.0 | 0.0 | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other current liabilities | 1.3 | 1.5 | | 4.6 | 4.8 | 6.8 | 8.7 | 6.1 |
| Total current liabilities | 14.8 | 13.3 | | 14.3 | 11.7 | 12.6 | 11.5 | 10.4 |
| Long-term debt | 24.6 | 24.5 | | 19.4 | 19.3 | 19.2 | | |
| Other liabilities | 1.8 | 0.0 | | 0.2 | 0.3 | 0.5 | 0.7 | 0.9 |
| Total liabilities | 41.2 | 37.8 | | 33.8 | 31.3 | 32.3 | 12.2 | 11.3 |
| |
| Shareholders' equity [+] | 147.7 | 173.4 | | 202.6 | 221.5 | 149.2 | 166.7 | 179.1 |
| Paid-in capital | 311.4 | 305.7 | | 297.8 | 294.2 | 216.1 | 213.4 | 211.0 |
| Retained earnings | -163.6 | -132.2 | | -95.2 | -72.7 | -66.9 | -46.7 | -31.8 |
| Tangible shareholders' equity | 147.7 | 173.4 | | 202.6 | 221.5 | 149.2 | 166.7 | 179.1 |
|